Psychiatry/Behavioral · PANCE / PANRE

Major Depressive Disorder (MDD)

Persistent depressed mood or anhedonia >=2 weeks with neurovegetative and cognitive symptoms causing functional impairment.

Also known as: MDD, depression, unipolar depression, clinical depression, major depression

Overview

A mood disorder defined by one or more major depressive episodes — >=2 weeks of depressed mood or anhedonia plus additional neurovegetative, cognitive, and psychomotor symptoms causing significant distress or functional impairment, without a history of mania or hypomania.

Epidemiology

Lifetime prevalence ~20% in US adults; 12-month prevalence ~8%. Female-to-male ratio ~2:1. Peak onset in 20s-30s but can occur at any age. Higher rates with chronic medical illness, perinatal period, and substance use.

Try two board-style Major Depressive Disorder questions

Real questions from the FirstPassPA bank, with the full explanation. Pick an answer — no signup, no email.

Question 1PsychiatryEasy
A 35-year-old woman presents with 3 weeks of persistent low mood, loss of interest in activities she previously enjoyed, fatigue, feelings of worthlessness, and difficulty sleeping, along with recurrent thoughts that she would be better off dead. She has no prior psychiatric history, no manic or hypomanic symptoms, and no substance use. She denies any specific plan or intent to harm herself. Which of the following is the most appropriate first-line pharmacotherapy?
  • ALithium carbonate
  • BAmitriptyline
  • CSertraline
  • DLorazepam
Reveal answer & full explanation
Correct answer: C — Sertraline
  • ALithium carbonate
  • BAmitriptyline
  • CSertraline
  • DLorazepam

Why Sertraline is correct

  • Depressed mood, anhedonia, fatigue, worthlessness, insomnia, and recurrent thoughts of death for more than 2 weeks meet criteria for major depressive disorder, with no manic history to suggest bipolar disorder.
  • Selective serotonin reuptake inhibitors such as sertraline are first-line pharmacotherapy for major depressive disorder per current APA guidance, owing to their favorable tolerability and safety, including low lethality in overdose when passive suicidal ideation is present.
  • SSRIs require 4-6 weeks for full effect and are continued 6-12 months after remission.

Why the others are wrong

  • Lithium carbonate — a mood stabilizer for bipolar disorder; with no manic or hypomanic history it is not indicated, a buzzword trap of matching 'mood' to a mood stabilizer.
  • Amitriptyline — a tricyclic antidepressant that is effective but not first-line because of anticholinergic side effects and high lethality in overdose, a particular concern given her thoughts of death (right-category-wrong-drug).
  • Lorazepam — a benzodiazepine that may transiently ease insomnia or anxiety but does not treat the underlying depression and carries dependence risk (symptomatic-anchoring trap).
Question 2PsychiatryMedium
A 65-year-old man has 3 months of insomnia, decreased appetite, and psychomotor slowing after losing his wife 4 months ago. He says, 'I wouldn't mind if I didn't wake up.' His son asks if this is 'normal grief.' Which of the following features most distinguishes major depressive disorder (MDD) from normal grief?
  • AExcessive crying and tearfulness
  • BPassive suicidal ideation
  • CYearning for the deceased
  • DInsomnia with reduced appetite
Reveal answer & full explanation
Correct answer: B — Passive suicidal ideation
  • AExcessive crying and tearfulness
  • BPassive suicidal ideation
  • CYearning for the deceased
  • DInsomnia with reduced appetite

Why Passive suicidal ideation is correct

  • Normal grief comes in waves, centers on yearning for the deceased, and preserves self-esteem, with any thoughts of death usually focused on joining or being with the lost person
  • Persistent passive suicidal ideation ('I wouldn't mind if I didn't wake up') reflects self-directed hopelessness and is a feature of major depressive disorder (MDD), not uncomplicated grief
  • Other features that flag MDD over grief: pervasive worthlessness/guilt, sustained (not wave-like) low mood, marked functional impairment, and meeting full MDD criteria for at least 2 weeks
  • This patient meets MDD criteria and warrants treatment, typically a selective serotonin reuptake inhibitor (SSRI) plus grief-focused psychotherapy

Why the others are wrong

  • Excessive crying and tearfulness — occurs in both normal grief and MDD, so it cannot discriminate between them; this is a buzzword-matching trap that picks the most emotionally salient symptom
  • Yearning for the deceased — the hallmark of normal grief (and prolonged grief disorder), not MDD, so it points away from the diagnosis; a confused-with-grief trap
  • Insomnia with reduced appetite — neurovegetative symptoms are equally common in uncomplicated grief and in MDD, so they do not separate the two; a trap that rewards picking the finding the patient obviously has
🔒 Free preview limit reached

Keep reading — start your free trial

You've read your 2 free diagnosis previews. Create your free account to unlock the full Major Depressive Disorder (MDD) outline — plus all 514 diagnoses, 6,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.

Free to start · No credit card · Cancel anytime

Risk factors

  • Personal or family history of mood disorder; first-degree relative confers 2-3x risk
  • Female sex, perinatal period, perimenopause
  • Chronic medical illness (CAD, stroke, diabetes, cancer, chronic pain, hypothyroidism)
  • Adverse childhood experiences, recent loss or psychosocial stressor
  • Substance use disorders; comorbid anxiety disorders
  • Medications: interferon, corticosteroids, isotretinoin, beta-blockers (modest signal)

Pathophysiology

Multifactorial. Dysregulation of monoaminergic neurotransmission (serotonin, norepinephrine, dopamine), HPA-axis hyperactivity with elevated cortisol, reduced hippocampal neurogenesis and BDNF, neuroinflammatory changes, and altered limbic-prefrontal connectivity. Genetic heritability ~40%.

Clinical presentation

Symptoms

  • Depressed mood most of the day, nearly every day (self-reported or observed)
  • Markedly diminished interest or pleasure in nearly all activities (anhedonia)
  • Significant weight change or appetite disturbance
  • Insomnia (especially early-morning awakening) or hypersomnia
  • Psychomotor agitation or retardation observable by others
  • Fatigue or loss of energy
  • Feelings of worthlessness or excessive/inappropriate guilt
  • Diminished concentration or indecisiveness
  • Recurrent thoughts of death, suicidal ideation, plan, or attempt

Signs / physical exam

  • Flat or constricted affect, slowed speech, poor eye contact
  • Tearfulness; psychomotor retardation or agitation
  • Poor grooming in severe cases
  • Cognitive testing may reveal pseudodementia in older adults (reversible with treatment)

Classic findings

SIG E CAPS mnemonic — Sleep, Interest, Guilt, Energy, Concentration, Appetite, Psychomotor, Suicidality. Five of nine including depressed mood or anhedonia x 2 weeks.

Differential diagnosis

  • Bipolar depression — Screen for past hypomania/mania (elevated energy + decreased need for sleep + goal-directed activity); antidepressant monotherapy can precipitate mania
  • Persistent depressive disorder (dysthymia) — Chronic low-grade depressed mood >=2 years without meeting full MDE criteria; may co-exist as 'double depression'
  • Adjustment disorder with depressed mood — Identifiable stressor within 3 months, symptoms insufficient for MDD, resolves within 6 months of stressor end
  • Grief / bereavement — Waves of yearning, preserved self-esteem, ability to experience positive emotion; consider MDD if symptoms persist, involve worthlessness, or include active SI
  • Hypothyroidism — Fatigue, weight gain, cold intolerance, constipation; check TSH in every new presentation
  • Substance-induced mood disorder — Symptoms emerge in context of intoxication or withdrawal (alcohol, sedatives, stimulants, opioids); resolves with abstinence
  • Premenstrual dysphoric disorder — Mood symptoms confined to luteal phase, remitting with menses; prospective daily ratings confirm
  • Seasonal affective pattern — MDEs with onset in fall/winter and remission in spring; consider light therapy

Diagnostic workup

Diagnostic criteria

DSM-5-TR: >=5 of 9 symptoms present for >=2 weeks, with at least one being depressed mood OR anhedonia. Symptoms must cause clinically significant distress/impairment, not be attributable to a substance or medical condition, and not be better explained by a psychotic or bipolar disorder. PHQ-9 >=10 supports diagnosis and tracks severity (5-9 mild, 10-14 moderate, 15-19 moderately severe, >=20 severe).

Labs

  • TSH to exclude hypothyroidism
  • CBC, BMP, vitamin B12, vitamin D
  • Urine drug screen if substance use suspected
  • HIV, RPR in select populations

Imaging

  • Neuroimaging not routine; consider MRI brain if new focal neurologic findings, atypical features, or first episode after age 50

Diagnostic algorithm

ClassExamplesStrengthsCautions
SSRIsertraline, escitalopram, fluoxetineFirst-line; broad efficacy; safe in overdoseGI upset, sexual dysfunction, hyponatremia, QT (citalopram)
SNRIvenlafaxine, duloxetine, desvenlafaxineComorbid pain, fatigueBP elevation, discontinuation syndrome
Atypical (NDRI)bupropionNo sexual side effects, activatingLowers seizure threshold; avoid in eating disorders
Atypical (NaSSA)mirtazapineSedation, appetite, weight gainSedation, weight gain
TCAnortriptyline, amitriptylineRefractory cases, neuropathic painAnticholinergic, cardiotoxic in overdose
MAOIphenelzine, tranylcypromineAtypical depressionTyramine crisis, serotonin syndrome
Antidepressant class comparison — first-line vs second-line options with key trade-offs.

Treatment

First-line

  • Psychotherapy — cognitive behavioral therapy (CBT) or interpersonal therapy (IPT); comparable to medication for mild-moderate episodes
  • SSRI — sertraline, escitalopram, fluoxetine (first-line pharmacotherapy; start low, titrate after 2-4 weeks; full effect at 6-8 weeks)
  • SNRI — venlafaxine, duloxetine, desvenlafaxine (consider with comorbid pain or fatigue)
  • Combine medication + psychotherapy for moderate-to-severe MDD
  • Lifestyle: aerobic exercise >=150 min/week, sleep hygiene, reduce alcohol, social engagement

Severe / psychotic / catatonic

  • Antidepressant + atypical antipsychotic (olanzapine, quetiapine, aripiprazole) for psychotic features
  • Electroconvulsive therapy (ECT) for severe, treatment-resistant, psychotic, catatonic, or pregnancy cases — rapid onset, highly effective
  • Inpatient admission if active suicidality, inability to care for self, or psychosis

Treatment-resistant (>=2 adequate trials)

  • Augment with bupropion, mirtazapine, lithium, or atypical antipsychotic (aripiprazole, quetiapine XR, brexpiprazole)
  • Esketamine intranasal (Spravato) under REMS for treatment-resistant MDD
  • Repetitive transcranial magnetic stimulation (rTMS)
  • ECT remains gold standard for severe refractory disease

Perinatal

  • Sertraline preferred during pregnancy and lactation
  • Avoid paroxetine in first trimester (cardiac malformation signal)
  • Brexanolone or zuranolone for postpartum depression
  • Screen with Edinburgh Postnatal Depression Scale

Second-line / adjunct

  • Bupropion (avoid in seizure disorder, eating disorder, active alcohol withdrawal) — useful when sexual side effects or sedation are limiting
  • Mirtazapine for prominent insomnia or weight loss
  • Tricyclics (nortriptyline, amitriptyline) reserved for refractory cases — overdose lethality limits use
  • MAOIs (phenelzine, tranylcypromine) — atypical depression; dietary tyramine restrictions

Complications

  • Suicide — lifetime risk ~5-8% in treated MDD; highest early in treatment and in first weeks after hospital discharge
  • Functional decline: occupational disability, relationship disruption
  • Comorbid substance use disorders
  • Worsened outcomes in CAD, diabetes, and post-stroke recovery
  • Chronic course — 50% recurrence after first episode, 70% after second, 90% after third

PANCE pearls

  • Always screen for past hypomania/mania before starting an antidepressant — unopposed antidepressants in bipolar disorder can precipitate mania or rapid cycling.
  • FDA black box warning: increased suicidal ideation in patients <25 during initial weeks of antidepressant treatment. Monitor closely.
  • Allow 4-6 weeks at therapeutic dose before declaring treatment failure. Partial response by week 4 predicts remission.
  • After full remission, continue antidepressant for >=6-12 months (first episode) or indefinitely (>=3 episodes or severe episode) to prevent relapse.
  • Discontinuation syndrome: dizziness, flu-like symptoms, paresthesias ('brain zaps'), insomnia — worst with paroxetine and venlafaxine; taper slowly.
  • USPSTF recommends screening all adults including pregnant/postpartum for depression with adequate systems for diagnosis and follow-up.

References

  • APA 2010 — American Psychiatric Association Practice Guideline for the Treatment of Patients with Major Depressive Disorder, 3rd ed. (2010)
  • USPSTF 2023 — Screening for Depression and Suicide Risk in Adults: USPSTF Recommendation Statement, JAMA 2023
  • DSM-5-TR — American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed, Text Revision (2022)
  • STAR*D — Rush AJ et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. Am J Psychiatry 2006

Practice Psychiatry/Behavioral questions on FirstPassPA

Turn this outline into retention. 6,500+ board-style questions with an AI tutor that explains every answer — free to start, no card required.

Answer the 2 free questions above → Get today's free question →

Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.